Liebel Frank, Lyte Peter, Garay Michelle, Babad Jeffrey, Southall Michael D
Preclinical Pharmacology, Skin Research Center, Johnson and Johnson Consumer Products, 199 Grandview Road, Skillman, NJ 08558, USA.
Arch Dermatol Res. 2006 Sep;298(4):191-9. doi: 10.1007/s00403-006-0679-8. Epub 2006 Jul 26.
Cutaneous fungal infections are frequently associated with an inflammatory component including irritated skin, itching and stinging/burning. Therapeutic anti-fungal agents that have anti-inflammatory activity have the potential to provide clinical benefit beyond fungus eradication. Recently, certain anti-fungal agents have been shown to have intrinsic anti-inflammatory activity, therefore we sought to determine the extent of the anti-inflammatory activity of these compounds. The anti-inflammatory activities of eight anti-fungal agents (butoconazole, ciclopirox olamine, fluconazole, miconazole nitrate, sertaconazole nitrate, terconazole, tioconazole and ketoconazole) were compared in a number of preclinical models of dermal inflammation and pruritus. While butoconazole, ciclopirox olamine, fluconazole, and miconazole nitrate were all found to have anti-inflammatory activity, only sertaconazole nitrate reduced the release of cytokines from activated lymphocytes and mitigated inflammation in animal models of irritant contact dermatitis and neurogenic inflammation. In addition, sertaconazole nitrate inhibited contact hypersensitivity and scratching responses in a murine model of pruritus. Furthermore, the in vitro and in vivo anti-inflammatory activity of sertaconazole nitrate was found to be greater than other topical anti-fungal agents examined. These studies demonstrate that topical administration of clinically relevant concentrations of sertaconazole nitrate resulted in an efficacious anti-inflammatory activity against a broad spectrum of dermal inflammation models and itch. The anti-inflammatory properties of sertaconazole may contribute to the efficacy of the drug in the treatment of cutaneous fungal conditions and provide greater anti-inflammatory activity compared with other anti-fungal agents.
皮肤真菌感染常伴有炎症成分,包括皮肤刺激、瘙痒和刺痛/灼痛。具有抗炎活性的治疗性抗真菌药物有可能在根除真菌之外提供临床益处。最近,某些抗真菌药物已被证明具有内在抗炎活性,因此我们试图确定这些化合物的抗炎活性程度。在一些皮肤炎症和瘙痒的临床前模型中比较了八种抗真菌药物(布康唑、环吡酮胺、氟康唑、硝酸咪康唑、硝酸舍他康唑、特康唑、噻康唑和酮康唑)的抗炎活性。虽然发现布康唑、环吡酮胺、氟康唑和硝酸咪康唑都具有抗炎活性,但只有硝酸舍他康唑能减少活化淋巴细胞释放细胞因子,并减轻刺激性接触性皮炎和神经源性炎症动物模型中的炎症。此外,硝酸舍他康唑在瘙痒小鼠模型中抑制接触性超敏反应和抓挠反应。此外,发现硝酸舍他康唑的体外和体内抗炎活性均大于所检测的其他局部抗真菌药物。这些研究表明,局部应用临床相关浓度的硝酸舍他康唑可产生针对广泛皮肤炎症模型和瘙痒的有效抗炎活性。舍他康唑的抗炎特性可能有助于该药物治疗皮肤真菌病的疗效,并与其他抗真菌药物相比提供更大的抗炎活性。